Cargando…

Unarranged territory in uncommon EGFR mutations

Detalles Bibliográficos
Autores principales:	Fujii, Hiroyuki, Okuma, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359962/ https://www.ncbi.nlm.nih.gov/pubmed/35958324 http://dx.doi.org/10.21037/tlcr-22-478

Ejemplares similares

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
por: Kitadai, Rui, et al.
Publicado: (2022)

Uncommon EGFR-Mutant NSCLC—One Drug Does Not Fit All
por: Wang, Yang, et al.
Publicado: (2023)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
por: Tan, Xueyun, et al.
Publicado: (2022)

Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
por: Brindel, Aurélien, et al.
Publicado: (2020)

Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation
por: Peng, Liang, et al.
Publicado: (2015)

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
por: Lin, Chien‐Yu, et al.
Publicado: (2023)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
por: Park, Dong-Guk
Publicado: (2011)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
por: Chiba, Masato, et al.
Publicado: (2017)

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort
por: Tankere, Pierre, et al.
Publicado: (2022)

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
por: Agbarya, Abed, et al.
Publicado: (2014)

A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC
por: Chen, Wufei, et al.
Publicado: (2021)

Cardiovascular and renal medicine, an expanding territory
por: Zoccali, Carmine, et al.
Publicado: (2011)

MMR-deficiency and BRCA2/EGFR/NTRK mutations
por: Gokare, Prashanth, et al.
Publicado: (2017)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Uncommon ophthalmology - Care for the rare
por: Honavar, Santosh G
Publicado: (2022)

EGFR mutations in sinonasal squamous tumors: oncogenic and therapeutic implications
por: Udager, Aaron M., et al.
Publicado: (2015)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin, Elisna, et al.
Publicado: (2018)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
por: Morita, Ayako, et al.
Publicado: (2021)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
por: Li, Kaidi, et al.
Publicado: (2017)

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

The management of postoperative recurrence of non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation: what is the best way?
por: Adachi, Hiroyuki, et al.
Publicado: (2022)

Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients
por: Guo, Gang, et al.
Publicado: (2021)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

Multiple mutations in the EGFR gene in lung cancer is rare but should not be forgettable
por: Miyata, Ryo, et al.
Publicado: (2022)

Personalized post-surgical care?—possible strategies for NSCLCs with EGFR mutation
por: Suda, Kenichi
Publicado: (2020)

Can we cure metastatic EGFR-mutated lung cancer today?
por: Christopoulos, Petros
Publicado: (2023)

Indigenous peoples’ territorial sovereign in the Amazon must be respected
por: Regional Health– Americas, The Lancet
Publicado: (2022)

Critical Care Research in Elderly Population: An Uncharted Territory
por: Todi, Subhash, et al.
Publicado: (2020)

Covering the territory: can Injury Prevention do better?
por: McClure, Roderick J
Publicado: (2021)

Provinces and Territories Are Overdue for an Update in Healthcare Funding Policies
por: Sutherland, Jason M.
Publicado: (2023)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
por: Kanazu, Masaki, et al.
Publicado: (2020)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
por: Chantharasamee, J., et al.
Publicado: (2019)

Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response
por: Pancrazzi, Alessandro, et al.
Publicado: (2021)

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma
por: Namba, Kei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gqbbjj0j5mispdj5mhlta0nvoo